A Pilot Study of CPT-11 and Cisplatin for Ovarian Clear Cell Adenocarcinoma
| Autor: | Toshitada Ogasawara, Koji Koyama, Yoshiyuki Tsuji, Tadashi Takemura, Susumu Adachi, Hiroaki Shibahara, Riichiro Kanazawa, Noriyuki Yamasaki |
|---|---|
| Rok vydání: | 1999 |
| Předmět: |
Adult
Oncology Cancer Research medicine.medical_specialty endocrine system diseases Cyclophosphamide Phases of clinical research Pilot Projects Irinotecan Gastroenterology Drug Administration Schedule Ovarian Clear Cell Adenocarcinoma Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Radiology Nuclear Medicine and imaging Ovarian Neoplasms Cisplatin Leukopenia business.industry General Medicine Middle Aged medicine.disease Regimen Toxicity Camptothecin Female medicine.symptom Ovarian cancer business Adenocarcinoma Clear Cell medicine.drug |
| Zdroj: | Japanese Journal of Clinical Oncology. 29:434-437 |
| ISSN: | 1465-3621 0368-2811 |
| DOI: | 10.1093/jjco/29.9.434 |
| Popis: | Background: Ovarian clear cell adenocarcinoma is known to have poorer prognosis than ovarian serous cystadenocarcinoma. Cyclophosphamide plus cisplatin has been the standard therapy for ovarian cancer, but ovarian clear cell adenocarcinoma dose not respond to this therapy. The treatment for ovarian clear cell adenocarcinoma has not been established. We planned a pilot study of CPT-11 and cisplatin for the treatment of ovarian clear cell adenocarcinoma. Methods: First, three patients were administered 70 mg/m 2 of cisplatin intravenously on day 1 and 60 mg/m 2 of CPT-11 intravenously on days 1, 8 and 15. Treatment was repeated every 4 weeks. Other patients were administered 75 mg/m 2 of cisplatin intraperitoneally on day 1 and 60 mg/m 2 of CPT-11 intravenously on days 1, 8 and 15. Treatment was repeated every 4 weeks. Results: A total of 10 patients were entered in this study and a total of 43 courses were administered. 1 CR, 1 PR and 1 PO were observed in patients with measurable lesion. Grade 3 leukopenia was experienced in seven patients, grade 3 thrombocytopenia in two and grade 3 anemia in five. Grade 3 liver toxicity was observed in one patient and grade 3 diarrhea in one patient. No grade 4 toxicity was experienced. Conclusion: CPT-11 plus cisplatin is feasible and has efficacy for ovarian clear cell adenocarcinoma. This regimen should be explored in a phase II study. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|